Current Programs

Polpharma Biologics has a robust and expanding pipeline of biosimilars currently in development to treat a number of conditions across major therapeutic areas. Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of six biosimilar candidates, with one finished the phase III and second started the phase I of clinical trials. We are highly focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.

 

Biosimilars Pipeline

Code / Molecule
Originator
Type
Therapeutic Area
Ranibizumab*
Lucentis
Biosimilar
Ophthalmology
PB006 / Natalizumab
Tysabri
Biosimilar
Multiple Sclerosis
PB007 / Ustekinumab
Stelara
Biosimilar
Immunology
PB014
Not disclosed
Biosimilar
Oncology
PB015
Not disclosed
Biosimilar
Oncology
PB016
Not disclosed
Biosimilar
Immunology
Early Tech Dev
Late Tech Dev
PhI
PhIII
Submission
Approval

*in partnership with Bioeq IP AG